Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
Dual Antiplatelet Therapy represents the main therapy for patients presenting with chronic
coronary syndromes and undergoing elective PCI. However, most of these patients are not
properly covered in terms of inhibition of platelets aggregation at the time of PCI, and are
exposed to an higher risk of microvascular damage which in turns might be responsible of
residual symptoms persistence and the findings of residual ischemia at the non-invasive
tests. In naïve patients, cangrelor can be administered at the time of PCI potentially
protecting coronary microcirculation. The aim of this randomized study is indeed to evaluate
the use of Cangrelor as compared with standard practice (with Clopidogrel) in terms of
incidence of coronary microvascular dysfunction following elective PCI of functionally
significant intermediate coronary stenoses. All consecutive patients, fulfilling inclusion
and exclusion criteria, will be enrolled and both FFR and CFR/IMR will be measured before and
after PCI. Platelet reactivity will be also evaluated mainly during PCI procedure. At 30 days
of follow up, patients will be interrogated about symptoms persistence and will be asked to
complete the specific Seattle Angina Questionaty (SAQ7). At 3 months a SPECT could be
performed in order to evaluate the presence of residual ischemic area in the myocardial
territory downstream to the treated vessel. With this study we will be able to evaluate the
potential benefit of using Cangrelor, as compared with standard therapy with Clopidogrel, in
terms of protection of coronary microcirculation during elective PCI and reduction of both
residual symptoms and ischemia at clinical follow up.